1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Genomic Medicines Accelerator Fund Call for Applications is sponsored by MIT Health and Life Sciences Collaborative (MIT HEALS). This program provides funding to support research useful or relevant to genome editing in the field of genomic medicines for the prevention or treatment of human disease, with IP obligations arising under a subaward from the Broad Institute.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Genomic Medicines Accelerator Fund – MIT HEALS Genomic Medicines Accelerator Fund Call for Applications Accelerating Innovation in Genomic Medicines The MIT Health and Life Sciences Collaborative (MIT HEALS) is now accepting applications for the Genomic Medicines Accelerator Fund.
This program will provide funding to support research useful or relevant to genome editing in the field of genomic medicines for the prevention or treatment of human disease and has IP obligations arising under a subaward from the Broad Institute. Funding Amount: Up to $200,000 in direct costs per lab-based PI per year (up to $100,000 in direct costs for ethics/social science/business projects) for up to 2 years.
Eligibility: MIT faculty and PIs; collaborative teams encouraged. No funds may go to non-MIT collaborators. Application Timeline: • Letter of Intent due January 30, 2026 • Full proposals invited February 6, 2026 • Applications due March 6, 2026 Award Notification: Late March 2026 Project Start Date: April 15, 2026 How to Apply: Submit Letter of Intent and—if invited—full proposal via the HEALS website.
The MIT HEALS Collaborative is dedicated to advancing transformative research that redefines how we understand and approach challenges in health and the life sciences. A broad swath of opportunities may be considered for this funding opportunity.
Examples of suitable topics include: research to develop new genome editing technologies or platforms novel delivery approaches for genome editing machinery genomic cell engineering for modeling or medical applications genome editing approaches to gain knowledge about precision medicine targets, mechanisms of drug action, and drug resistance patterns.
artificial intelligence approaches to improve genomic medicine design or deployment ethical considerations, socio-economic analyses, or business cases related to genome editing medicines or precision medicines Other topics can be considered if aligned with genomic medicine strategies. All disease areas will be considered. Projects related to germline editing will not be considered.
We encourage proposals from across all Schools, the College, Departments, and units at MIT. Proposals involving collaborative or interdisciplinary teams are encouraged, though single-PI proposals are permitted. MIT faculty and PIs whose work aligns with the topics above are eligible.
Although the work can involve collaborations with Broad Institute investigators, no funds can be distributed to non-MIT collaborators. Each award will be up to $200k per year in direct costs per PI for lab-based research projects. Teams of PIs may request up to $200k direct costs per lab-based PI per year (e.g., a team of 2 lab-based PIs can request $400k per year in direct costs).
Awards in ethics, social sciences, and business will be up to $100k per year in direct costs. These awards can but are not required to be collaborative with lab-based projects. Full overhead at MIT’s current rate will be applied to all funded projects.
Projects may be up to 2 years in duration. Initial grants will vary based on the requested budget for a given project or team and applicants will be eligible to submit renewal applications if satisfactory progress is met toward milestones. We anticipate funding approximately 4 lab-based PIs in the first year (e.g., two teams of 2 PIs), or 3 lab-based PIs and 2 PIs in ethics, social sciences, or business, for a total of $1.
3M. Additional awards will be available in the following two years. Funds may not be co-mingled from other sources.
Institute-wide symposium : PIs may be asked to showcase their work at the HEALS annual symposium, engaging with the broader research community. Quarterly reporting : Each quarter, PIs will be required to provide a short project update. Recipients must promptly disclose any intellectual property (IP) developed in the course of the research to MIT’s Technology Licensing Office (TLO).
Any IP developed using this funding will be encompassed under MIT’s relationship with the Broad Institute and also includes a time limited option right for Editas Medicine to take a commercial license to the IP. Full proposals invited, with feedback if applicable Background IP review for full proposals Successful applicants notified and proposals routed in Kuali Coeus Applications are now closed.
Please direct questions to: MIT HEALS – mit-heals@mit. edu Partner with us to collaborate with top experts, industry leaders, and visionary researchers. Empower the future of health innovation— support MIT HEALS with your donation.
According to the current listing, eligibility includes: MIT faculty and Principal Investigators; collaborative teams are encouraged. No funds may go to non-MIT collaborators. Confirm the full requirements in the official notice before applying.
The current listing shows up to $200,000 in direct costs per lab-based PI per year (up to $100,000 in direct costs for ethics/social science/business projects) for up to 2 years. Verify award ceilings, matching requirements, and allowable costs in the official notice.
Genomic Medicines Accelerator Fund Call for Applications is funded by MIT Health and Life Sciences Collaborative (MIT HEALS). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
MIT HEALS Seed Grant Call for Applications is sponsored by MIT Health and Life Sciences Collaborative (MIT HEALS). This program provides seed funding to support collaborative projects at the cutting edge of health and life sciences with the goal of catalyzing new interactions, developing new technologies and methodologies, generating core datasets, and accelerating discovery.
Genomic Medicines Accelerator Fund is sponsored by MIT Health and Life Sciences Collaborative (MIT HEALS). This fund supports research useful or relevant to genome editing in the field of genomic medicines for the prevention or treatment of human disease. It encourages proposals from across all Schools, the College, Departments, and units at MIT, with an emphasis on collaborative or interdisciplinary teams.
Illuminating AD/ADRD Genome to Enable Precision Genomic Medicine is sponsored by National Institute on Aging (NIA). This forecasted Notice of Funding Opportunity (NOFO) will solicit applications for integrative, cross-disciplinary projects aimed at scaling up mechanistic studies to understand the genomic underpinnings of Alzheimer's Disease and Alzheimer's Disease-Related Dementias (AD/ADRD) to guide precision medicine approaches.
D2M-AIP is the discovery-end component of PRIMED-AI, the NIH Common Fund's new Precision Medicine with AI: Integrating Imaging with Multimodal Data program, which the NIH Council of Councils approved as a Common Fund program on April 21, 2025 and which launched five coordinated funding opportunities in 2026. The specific target here is AI-enabled, image-centered, multimodal clinical decision support tools - systems that fuse clinical imaging with other health data streams such as genomics, pathology, laboratory values and electronic health records - developed explicitly as Software as a Medical Device. Two features distinguish this announcement from ordinary NIH AI funding. First, the academic-industrial partnership requirement is structural rather than decorative: projects are meant to be pre-competitive collaborations positioned for eventual commercialization, so a purely academic team without an industry partner is unlikely to be competitive. Second, the phased UG3/UH3 mechanism means the award is gated - the UG3 phase (up to $450,000 direct costs per year) funds development against defined milestones, and transition to the UH3 phase (up to $800,000 direct costs per year) depends on meeting them. Applicants should write the milestone plan as a first-class part of the proposal rather than an afterthought. The emphasis on novel data integration and new AI model development means incremental applications of existing architectures to a new dataset will read poorly; reviewers are looking for methodological advance paired with a credible regulatory and deployment path. Eligibility is broad, including foreign organizations, which is unusual among the five PRIMED-AI announcements - the Validation Center, Logistics Center and Playbook opportunities all exclude foreign entities. Teams whose tool is already a validated prototype rather than a concept should look instead at the companion Model-to-Clinic announcement, RFA-RM-27-013, which shares this deadline.
The U.S. Government Policy for Stopping High-Risk Life Sciences Research, released July 28, 2026 under EO 14292 and implemented at NIH through NOT-OD-26-101, replaces mitigation with prohibition. It bans dangerous gain-of-function research outright, gates potential DGOF behind government-wide review, and creates International Research of Concern — a research-security regime wearing biosafety clothing. Penalties run to five-year debarment and False Claims Act exposure.
Read articleAwards slashed by half, life sciences applicants rejected at 95%, and the White House steering which fields get funded. How the GRFP went from funding the person to funding the priority.
Read articleAfter a rare gap with zero active omnibus NOFOs, NIH has reissued its SBIR/STTR parent announcements — collapsing four solicitations into two, adding a Strategic Breakthrough bridge and a Commercialization Readiness Pilot, and reopening the funnel with a September 5, 2026 receipt date. Here are the exact solicitation numbers, the new budget ceilings, what actually changed, and how a small business should sequence its submission.
Read article